Developer of mRNA therapeutics for infectious diseases. It has two proprietary platforms for SNIM RNA technology (Stabilized Non-Immunogenic mRNA) for transcript therapy and SNIM RNA delivery system. The platforms enable the designing of mRNA for the protein of interest and chemical modification of the nucleotide backbone to bypass the innate immune response and targeted delivery. The pipeline includes therapeutics for COVID-19, respiratory diseases, and Primary ciliary dyskinesia (PCD). Ethris operates in the Pulmonology, Genomics, Gene Therapy sectors. The company focuses on Diversified, Therapeutics. The company has raised $31.3M in Series B funding. Notable investors include Europa, Laureus Capital, EU4health, Gates, Orbimed. Ethris was founded in 2009 and is headquartered in Planegg, Germany.
← All startups
Ethris
Series BDeveloper of mRNA therapeutics for infectious diseases. It has two proprietary platforms for SNIM RNA technology (Stabilized Non-Immunogenic mRNA) for transcript therapy and SNIM RNA delivery system. The platforms enable the designing of mRNA for the protein of interest and chemical modification of the nucleotide backbone to bypass the innate immune response and targeted delivery. The pipeline includes therapeutics…
About
Business model
Pulmonology > Drugs > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
EuropaLaureus CapitalEU4healthGatesOrbimedWalter GusthavBernd Gansbacher
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.